COMP <GO>
ORKA vs ABBV // FORWARD P/E MULTIPLE
Oruka Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ORKA 3
— ABBV 11
▲ FORWARD P/E MULTIPLE LEADER: ORKA
LAST: $96.87 (+0.23%) • MKT CAP: $6.40B
forward-pe
28.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORKA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORKA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.80% | 29.00% | -47.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | 3.47% | -4.85 | ABBV | /fcf-yield <GO> |
| Operating Margin | -6.80% | 24.60% | -31.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -5.90% | 6.90% | -12.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -4.40% | 8.60% | -13.00 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | ORKA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | ORKA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 72.8 | -5.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 1.15 | -0.02 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 28.0x | 113.1x | -85.10 | ORKA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.40B | $513.86B | -$507.46B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORKA REV | ABBV REV | ORKA GROSS % | ABBV GROSS % | ORKA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$88.4M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$58.0M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$5.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORKA // BETA 1.13
ABBV // BETA 1.15